Results 151 to 160 of about 225,158 (305)
Mitochondria and the Actin Cytoskeleton in Neurodegeneration
ABSTRACT Mitochondrial dysfunction and cytoskeletal disorganization are widely recognized hallmarks of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
Shivani Tuli +3 more
wiley +1 more source
Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations
Major depressive disorder is a highly prevalent psychological disorder worldwide and its main treatment is the use of Selective Serotonin Reuptake Inhibitors. However, few studies have demonstrated the relationship between the presence of genetic variants in pharmacogenes and the efficacy of these drugs, especially in populations with a unique genetic ...
Kaio Evandro Cardoso Aguiar +9 more
wiley +1 more source
Lei Geng,1,2 Sheng Zhang,1,2 Jun Yan,1,2 Runlan Wang1,2 1Department of Psychiatry, Wuhan Mental Health Center, Wuhan, People’s Republic of China; 2Department of Psychiatry, Wuhan Hospital for Psychotherapy, Wuhan, People’s Republic of ChinaCorrespondence:
Geng L, Zhang S, Yan J, Wang R
doaj
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott +7 more
wiley +1 more source
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland +48 more
wiley +1 more source
Bioactivation and metabolism of MDMA prodrugs: MDMA‐Trp, MDMA‐Lys, MDMA‐Gly showed unique urine screening targets only for MDMA‐Trp, while biomarkers for MDMA‐Lys and MDMA‐Gly consisted of MDMA and known MDMA metabolites. Conversion of amino acid prodrugs to MDMA in pHLS9, zebrafish embryos, and humans. ABSTRACT 3,4‐Methylenedioxymethamphetamine (MDMA)
Simon K. Wellenberg +6 more
wiley +1 more source
ABSTRACT Objective Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety.
Neha Sahota +8 more
wiley +1 more source
ABSTRACT Objective Anorexia nervosa (AN) is a severe eating disorder associated with extreme weight loss, hyperactivity, and amenorrhea. Neuroimaging studies revealed brain atrophy and disruption of white matter integrity in the corpus callosum (CC) of patients with AN. However, the underlying pathophysiological mechanisms remain unclear.
Stephan Lang +9 more
wiley +1 more source

